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Abstract 
 
Objective: During the last years, left ventricular dysfunction in diabetes was intensely studied and it is recognized as a 
complication of diabetes, while data regarding the right ventricular dysfunction is still incomplete. 
The aim of this study was to find a correlation between inflammatory biomarkers, adiponectin and right ventricular strain 
and strain rate properties in patients with diabetes mellitus type 2. 
Methods:We studied 29 patients with type 2 diabetes mellitus (DM), with coexisting cardiovascular complications, 
coronary artery disease and high blood pressure (group 1- DM+CV,  aged 61.2 ±4.2 years);  and 22 patients with type 2 
diabetes and controlled high blood pressure only, with no other coexisting cardiovascular complications (group 2- DM, 
aged 60.86 ±4.4 years).   
We evaluated the right ventricular (RV) function through Vector Velocity Imaging (VVI)and determined the 
inflammatory profile through assessment of the following biomarkers: high sensitivity C- reactive protein (hsCRP), tumor 
necrosis factor-alpha (TNF-alfa), lipoprotein associated phospholipase A2 (Lp-PLA2) and adiponectin level for each 
patient.  
Results:VVI revealed significantly lower values of systolic strain and strain rates (SR) in the basal segment of the RV 
free wall in group I patients (DM+CV) as compared to group II patients (DM) which indicates higher impairment of RV 
systolic function in patients with diabetes and other cardiovascular complications. In both groups strain and strain rate 
values were correlated with Lp-PLA2 activity levels.  
Conclusions:In Type 2 diabetes mellitus we identified a low-grade inflammatory status correlated with right ventricular 
systolic dysfunction.  
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Introduction
Type 2 diabetes mellitus (DM) is characterized 
by a low-grade inflammatory status and endothelial 
dysfunction, which substantially potentiates the risk of 
developing cardiovascular diseases. The impact of 
diabetes leads to myocardial dysfunction, which is initially 
sub-clinical and might lead finally to diabetic 
cardiomyopathy and heart failure (HF). 
In the latest years, a lot of evidence has been  
collected regarding left ventricular dysfunction as a 
common complication of diabetes mellitus [1], while data 
regarding right ventricular (RV) performance and the 
impact of different inflammatory factors on its 
performance, is still incomplete.  
It becomes imperative to identify some 
biomarkers footprints, which could reveal the 
asymptomatic patients at high risk of evolution to left and 
right ventricular myocardial dysfunction, making effective 
prevention possible.  
Right ventricular function, has been recognized 
as a significant indicator of clinical outcome and 
prognostic value in heart failure, myocardial infarction, 
pulmonary embolism and more recent in diabetes, too. [2-
5]. Journal of Medicine and Life Vol. 5, Issue 1, January‐March 2012 
  75
It is already known that lipoprotein-associated 
phospholipase A2 (Lp-PLA2), is a risk marker for 
endothelial dysfunction in patients with type 2 diabetes 
and recent data suggest that Lp-PLA2 might be a 
biomarker constantly correlated with HF, regardless of 
aetiology [6-7]. Elevated plasma values of Lp-PLA2 in 
heart failure with preserved ejection fraction (HFpEF) are 
consistent with the exacerbated inflammatory status [8]. 
Recent research proved that adiponectin (Adpk) 
is correlated with the presence of atherogenic 
dyslipidemia and with N-terminal prohormone of brain 
natriuretic peptide (NT-proBNP) concentration but not with 
markers of systemic inflammation such as IL-6 or hsCRP 
in patients with manifested coronary heart diseases [9]. 
Data collected from current research indicate diabetic 
disease-specific alterations in the biochemical 
parameters, Adpk level is inversely correlated with hsCRP 
in end-stage renal disease patients [10]. 
In this study, we have evaluated Lp-PLA2 
activity, Adpk, TNF-alfa and hsCRP, in relation with the 
right ventricular parameters and tried to determine the 
initial, asymptomatic effects of DM and high blood 
pressure on the right ventricular systolic function.   
In addition, Lp-PLA2 activity and levels of Adpk, 
TNF-alfa and hsCRP, correlated to, or preceding 
echocardiographic findings, may improve the early 
diagnosis of cardiovascular complications in diabetic 
patients. 
Methods 
Study population  
The study included 51 patients with diabetes 
mellitus type 2 (DM type 2), screened between Jan 2010-
March 2011.  Patients were divided into two groups: 
group 1, consisting of 29 patients with DM type 2, high 
blood pressure ( HBP) and known coronary artery disease 
(CAD) and group 2, consisting of 22 patients with DM type 
2 and HBP, without CAD. For group 2 patients, CAD was 
excluded by negative results on treadmill test.  
Other exclusion criteria were: pulmonary 
hypertension, HF class III-IV NYHA, Left Ventricular 
Ejection Fraction (LVEF) < 45%, renal failure, hepatic 
failure, recent stroke, Transient Ischemic Attack (TIA) or 
acute myocardial infarction in last 6 months, absence of 
sinus rhythm,  neoplasm, patients taking anti-
inflammatory medication and poor quality of 
echocardiographic parameters. The characteristics of the 
studied population are presented in Table 1.  
Patients underwent clinical examination, routine 
laboratory tests, resting or treadmill test ECG, 
echocardiography (Velocity Vector Imaging- VVI). The 
treadmill test was performed according to the Bruce 
protocol using a positive response defined as the 
occurrence of at least 1-mm ST segment depression in 
comparison with the basic line tracing. Patients with BMI 
over 30 were considered obese. HBP was defined as 
documented systolic blood pressure ≥140 mmHg and /or 
diastolic blood pressure ≥90 mmHg, or by having anti-
hypertensive treatment ongoing. DM type 2 was 
controlled by oral anti-diabetic medication and specific 
diet. Concomitant medications consist of: ACE inhibitors, 
statins, beta-blockers, calcium channel blockers, aspirin, 
clopidogrel, nitrates, as per their specific diagnosis. 
Echocardiography was performed on Acuson Sequioa 
System 256 (Siemens).  
The VVI concept is based on the fact that during 
a cardiac cycle, tissue moves from one point to the next, 
and by multiple speckle tracking algorithms we are able 
through VVI to identify the tissue movements at every 
point, allowing analysis of strain and strain rate (SR), in 
longitudinal, radial or circumferential directions. In our 
study, we followed only the longitudinal parameters and 
we draw one trace on the RV endocardial border at end-
systole, followed by the automatic endomyocardial border 
tracing throughout all cardiac cycle. For strain and strain 
rate measuring, we averaged three cardiac cycles with a 
frame rate set at 31 frames per second. Regional 
parameters were calculated for RV for the free wall, basal 
and mid points, from an apical four-chamber image.   
All plasma samples were frozen and stored at -70°C- until 
analysis.  Lp-PLA2 activity was measured using the 
spectrophotometric method described by Kosaka et al. 
using the Azwell Auto PLA2-LDL kit [11]. Enzymatic 
activity is expressed through IU/L. Adpk, hsCRP and 
TNF-alfa, were determined through ELISA. 
 
Table 1. Characteristics of studied population, in investigated 
groups 
 
 
 
 
 
 
 
 
 
 
 
 
Statistical Analysis 
The statistical analysis was performed with the 
SPSS statistical package. The values presented are 
mean values ± SD. The following statistical tests were 
used:  Student’s two-tailed t-test, ANOVA, Pearson and 
Spearman rank correlation tests, linear regression. P 
value of <0.05 was considered statistically significant.  
Results 
In group 1, patients with type 2 diabetes and 
cardiovascular disease, the Lp-PLA2 activity was 
significantly higher, with mean value (SD) 419.46 UI 
(76.21), compared to values detected for patients with 
Group 1 (n= 29) Group 2 (n= 22)
Mean±SD Mean
Age 61,207 ± 4,279 60,864 ± 4,422
Male: Female (%) 28:72(%) 46: 54 (%)
Duration of Diabetes 
(years) 5,21 ± 2,874 4,41 ± 2,365
Fasting Glucose ( mg/dl) 113,62 ± 11,562 109,59 ± 6,239
HbA1C (%) 7,639 ± 0,4368 7,445 ± 0,3912
Body mass index (BMI) (kg/m²) 34,31 ± 2,62 32,95 ± 2,535
Waist (cm) 114,76 ± 11,463 108,55 ± 22,262
Obesity (%) 91(%) 86,5(%)
Sistolic blood pressure (SBP) 147,41 ± 8,826 146,82 ± 7,645
Diastolic blood pressure (DBP) 90,34 ± 4,805 90,23 ± 5,45
Leucocites 6141,38 ± 722,85 5177,27 ± 607,831
LDL 153,28 ± 16,215 151,82 ± 9,505
HDL 40,72 ± 4,366 44,5 ± 5,475Journal of Medicine and Life Vol. 5, Issue 1, January‐March 2012 
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diabetes and without CVD (group 2), where Lp-PLA2 
activity mean value (SD) was 307.22 UI (19.01).  As 
noticed also in other studies, values of CRP and TNF-alfa, 
were higher in group 1 (DM+CVD), than in group 2(DM 
only). (Table 2) 
For Adpk there was none correlation identified 
with any investigated parameters in group 1 patients. In 
group 2, we identified a negative correlation with 
SbasalVR (p<0.05) as well as a negative correlation with 
Lp-PLA2 (p<0.01). 
For both investigated groups, CRP values were 
not correlated with any RV echocardiographic 
parameters, but for CRP it was noticed a positive 
correlation with TNF-alfa for both groups (p< 0.05). And in 
addition, for group 2, we noticed a positive correlation 
between hsCRP and Lp-PLA2 (p<0.01). 
 
Table 2. Mean value and standard deviation for CRP, TNF-alfa, Adpk, Lp-PLA2, in investigated groups 
Mean±SD Mean±SD
CRP  4,924 ± 0,373 4,680 ± 0,235
TNFalfa 17,155 ± 5,107 16,061 ± 0,503
Adpk  4,466 ± 0,475 4,950 ± 0,254
Lp-PLA2 419,46 ± 76,21 307,22 ± 19,01
Group 1 (n= 29) Group 2 (n= 22)
 
 
Lp-PLA2 activity was significant statistically negative correlated with LVEF in both groups (p<0.01) and positive 
correlated with RV investigated parameters (p<0.01). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
We found significantly lower values of systolic 
strain and strain rates in the basal segment of the RV free 
wall in group 1 patients (DM+CV)  as compared with 
group 2 patients (DM) indicating higher impairment of RV 
systolic function within patients with diabetes and other 
cardiovascular complications. (Table 3) 
Table 3. Mean value and standard deviation for S/SR for basal 
and mid RV free wall, in investigated groups 
 
 
 
 
 
We identified significantly differences between 
groups for hsCRP, Adpk, SbasalRV, SmidRV, SRmidRV 
and Lp-PLA2 (p <0.01). 
Discussions 
According to the World Health Organization 
(WHO), the cardiovascular diseases are the number one 
cause of deaths worldwide, responsible for over 30% of 
all global deaths annually. Diabetes is known as a risk 
factor for CVD, the risk being increased by 2 to 4 times 
compared with adults without diabetes, and this 
determines the development of heart failure, sometimes 
even in the absence of its frequently coexisting 
comorbidities HBP or CAD.   
In the last ten years, there has been a lot of 
evidence accumulated regarding left ventricular 
dysfunction (systolic and diastolic) in diabetic patients; 
however, less research has been done for identifying the 
right ventricular dysfunction. A recent study investigated 
left ventricular strain and strain rates in diabetic patients. 
This study concluded that left ventricular longitudinal 
systolic and diastolic functions were impaired, while the 
circumferential and radial functions are preserved in 
patients with uncomplicated type 2 diabetes mellitus [1]. 
Also, a study done in type 1 diabetes mellitus patients 
proved that before any development of systolic 
Mean±SD Mean±SD
SbasalVR -14,069 ± 1,791 -15,568 ± 1,004
SmidVR -17,448 ± 1,526 -18,636 ± 0,915
SRbasalVR -0,9483 ± 0,414 -1,102 ± 0,228
SRmidVR -0,960 ± 0,090 -1,200 ± 0,362
Group 1 (n= 29) Group 2 (n= 22)Journal of Medicine and Life Vol. 5, Issue 1, January‐March 2012 
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dysfunction, the diastolic performance is altered, in both 
ventricles, suggesting that these alterations in myocardial 
function could be attributed to ventricular interdependence 
as well as to the global effect of diabetes on cardiac 
function [12]. 
Until now, none study has been published 
regarding relation between inflammatory biomarkers and 
right ventricular strain and strain rate in diabetic patients. 
We have included in our evaluation the Lp-LPA2 activity 
enzyme which is considered a link between lipid 
metabolism and low-grade inflammation and 
characteristic marker for cardiovascular or metabolic 
diseases, being considered also a valuable predictor of 
CVD. The West of Scotland Coronary Prevention Study 
(WOSCOPS) demonstrated that high levels of Lp-PLA2 
were associated with a two-fold increased risk of CHD. 
This relationship was valid also after taking into account 
the traditional CV risk factors and other inflammatory 
markers (including hsCRP) [13]. It is worth mentioning 
that recent research has identified that Lp-PLA2 may be 
in fact superior to other inflammatory markers, such as 
hs-CRP, due to its specificity and minimal bio-variation 
[14]. In addition, Lp-PLA2 is now recognized as a marker 
of oxidative stress and vascular inflammation which has a 
relative unique characteristic being independent from BMI 
and insulin resistance [15]. 
In our study, the higher values obtained in group 
1 patients (DM+CVD) for Lp-PLA2 (p<0.01) are in 
correlation with the inflammatory state characteristic of 
those patients. Furthermore, we found a significant but 
modest inverse correlation to HDL cholesterol, a finding 
consistent with many studies [16,17], but not all [18]. 
Interestingly, hsCRP did not correlate with any 
RV echocardiographic parameters, while Lp-PLA2 proved 
strong positive correlation with all investigated 
parameters. For group 1 patients ( DM+CVD), Adpk did 
not correlate with any investigated parameters of right 
ventricular dysfunction, a  finding consistent with other 
studies [19]; while for group 2, we detected a negative 
correlation SbasalVR (p<0.05) as well as a negative 
correlation with Lp-PLA2 (p<0.01). This finding might 
suggest that for uncomplicated DM, Adpk might be a 
potential marker of underlying mechanisms linking the 
diabetic state to cardiac abnormalities [20]. 
We noticed a higher impairment of right 
ventricular longitudinal systolic function in group 1, 
compared with group 2, being statistical significant for 
SbasalRV, SmidVR and SRmidVR (p<0.01).  
Similar results regarding RV echocardiographic 
parameters in diabetic patients were recently detected 
through 3D echo, stating the right ventricular systolic and 
diastolic dysfunction in diabetic patients [21]. 
By assessing the inflammatory profile of diabetic 
patients, it has been revealed that, even those 
asymptomatic for CVD, have a continuous inflammatory 
state, together with a decrease in RV systolic function.   
 
Limitations 
Due to angle dependent strain measurements, 
there should be caution in interpretations of strains when 
tissue direction deviates more than 30° from the beam 
direction. This could be a significant limitation of this 
technique, and reposition of transducer might help to 
correct this issue. Another limitation of this technique is 
the normal beat-to-beat variation in stroke volume that 
could explain why strain profiles do not always return to 
exactly same point of baseline at end diastole. That’s why 
for this study we averaged three cardiac cycles.  
Also, this is a cross-sectional study, with data collected at 
a given time-point, and due to this, it could not provide 
prognostic value of inflammatory markers. It is necessary 
to extend the study with a follow-up period. 
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